Bortezomib
Childhood Acute Lymphoblastic Leukemia
Explore 65 assets in Childhood Acute Lymphoblastic Leukemia →Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Tanja Andrea Gruber
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04996160CT.gov Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT03643276CT.gov Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | — | Recruiting | — | — | — |
NCT03390387CT.gov Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015) | — | Unknown | — | — | — |
NCT00873093CT.gov Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bortezomib (this asset) | Tanja Andrea Gruber | P3 | BB · 65 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
| Cytarabine | Children's Oncology Group | P3 | BBB |
| Nivestim | St. Jude Children's Research Hospital | P3 | BBB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P3 | BBB |
| Mercaptopurine Anhydrous | The Children's Hospital of Zhejiang University School of Medicine | P3 | BBB |
| Etoposide | Martin Schrappe | P3 | BBB |
| Pegaspargase | University of Chicago | P3 | BBB |
| Asparaginase | Therapeutic Advances in Childhood Leukemia Consortium | P3 | BBB |
+42 more in the Childhood Acute Lymphoblastic Leukemia cohort
Other indications for Bortezomib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | BBB · 73 |
| Follicular Lymphoma | — | P2 | BB · 71 |
| Waldenstrom Macroglobulinemia | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bortezomib in Childhood Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bortezomib-childhood-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →